Health system readiness is crucial to the successful integration of innovative interventions into clinical practice. As radioligand therapy is a highly multidisciplinary, specialised treatment, its integration into existing models of cancer care requires planning that extends beyond traditional health policy. Assessing the readiness of a health system can help identify barriers to integration, which can then be addressed through evidence-driven policy actions.
The Radioligand Therapy Assessment Framework was developed by The Health Policy Partnership and an International Expert Advisory Group to evaluate the extent to which radioligand therapy is currently integrated within key areas of a health system, and identify what is needed to successfully integrate it into cancer care.
This framework has already been applied to the UK and US with guidance from national Expert Advisory Groups.